This document is scheduled to be published in the Federal Register on 03/13/2017 and available online at https://federalregister.gov/d/2017-04808, and on FDsys.gov

[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended

(5 U.S.C. App), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions

could disclose confidential trade secrets or commercial property such as patentable material, and

personal information concerning individuals associated with the grant applications, the

disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Nicotinic Immune Modulation in the Presence of HIV-1 Infection (R01)

Date: March 22, 2017

Time: 11:00 AM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

1

Contact Person: Shang-Yi Anne Tsai, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

Division of Extramural Research

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 4228, MSC 9550

Bethesda, MD 20892

301-827-5842

shangyi.tsai@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems

for Prevention, Treatment and Control (UG3/UH3)

Date: March 24, 2017

Time: 8:00 AM to 12:00 PM

Agenda: To review and evaluate cooperative agreement applications

Place: Courtyard by Marriott Chevy Chase

5520 Wisconsin Avenue Chevy Chase, MD 20815

Contact Person: Hiromi Ono, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse National Institutes of Health, DHHS

6001 Executive Boulevard, Room 4238, MSC 9550

Bethesda, MD 20892

301-827-5820

hiromi.ono@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Hepatitis C Virus (HCV) Advanced Molecular Detection in Support of Systems for Prevention, Treatment and Control of HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug

Epidemics in the Unite

Date: March 24, 2017

Time: 12:30 PM to 5:00 PM

Agenda: To review and evaluate cooperative agreement applications

Place: Courtyard by Marriott Chevy Chase

5520 Wisconsin Avenue Chevy Chase, MD 20815

Contact Person: Hiromi Ono, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse National Institutes of Health, DHHS

6001 Executive Boulevard, Room 4238, MSC 9550

Bethesda, MD 20892

301-827-5820

hiromi.ono@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

2017 Loan Repayment

Date: March 26, 2017

Time: 10:00 AM to 5:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard Rockville, MD 20852 (Virtual Meeting)

Contact Person: Lyle Furr

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse, NIH, DHHS

Room 4227, MSC 9550 6001 Executive Boulevard Bethesda, MD 20892-9550

301-827-5702 lf33c.nih.gov

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: March 7, 2017

Natasha M. Copeland, Program Analyst
Office of Federal Advisory Committee Policy
[FR Doc. 2017-04808 Filed: 3/10/2017 8:45 am; Publication Date: 3/13/2017]